High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3794-3799

  Warnecke Eberz, Ute ^a   Metzger, Ralf ^a   Miyazono, Futoshi ^a,b   Baldus, Stephan E ^a   Neiss, Susanne ^a   Brabender, Jan ^a   Schaefer, Hartmut ^a   Doerfler, Walter ^a   Bollschweiler, Elfriede ^a   Dienes, Hans P ^a   Mueller, Rolf P ^a   Danenberg, Peter V ^c   Hoelscher, Arnulf H ^a   Schneider, Paul M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CISPLATIN; FLUOROURACIL; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXCISION REPAIR; EXCISION REPAIR CROSS COMPLEMENTING 1 GENE; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

ADULT; AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; DNA; DNA DAMAGE; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 2542603960     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0079     Document Type: Article

References (33)

1. Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options Oncol 2002;3:475-85.
2. MRC Esophageal Study Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 2002;359:1727-33.
3. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
4. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
5. Kelsen DP. Multimodality therapy of esophageal cancer: an update. Cancer J 2000;6(Suppl 2):S177-81.
6. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig 1994; 94:703-8.
7. Murray D, Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 1996;364:217-26.
8. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science (Wash DC) 2001;291:1284-9.
9. You JS, Wang M, Lee SH. Biochemical analysis of damage recognition process in nucleotide excision repair. J Biol Chem 2003;278: 7476-85.
10. Houtsmuller AB, Rademakers S, Nigg AL, et al. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science (Wash DC) 1999;284:958-61.
11. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16: 309-16.
12. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
13. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8: 2286-91.
14. Bollschweiler E, Schroeder W, Hoelscher AH, Siewert JR. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000;87:1106-10.
15. Schroeder W, Moenig SP, Baldus SE, et al. Frequency of nodal metastases to the upper mediastinum in Barrett's cancer. Ann Surg Oncol 2002;9:807-11.
16. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer (Phila) 1997;80:1011-20.
17. Junker K, Thomas M, Schulmann K, et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469-77.
18. Union Internationale contre le Cancer. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours, 5th ed. New York: Wiley; 1997.
19. Tokuchi Y, Hashimoto T, Kobayashi Y, et al. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer 1999;80:1623-9.
20. Dabholkar MD, Berger MS, Vionnet JA, et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995;55:1261-6.
21. Metz CE, Goodenough DJ, Rossmann K. Evaluation of receiver operating characteristic curve data in terms of information theory, with applications in radiography. Radiology 1973;109:297-303.
22. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24: 331-44.
23. Melton DW, Ketchen AM, Nunez F, et al. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998;111: 395-404.
24. Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 2002;22:21-6.
25. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-7.
26. Selvakumaran M, Pisarcik DA, Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63:1311-6.
27. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst (Bethesda) 1992;84:1512-7.
28. Nathrath M, Kremer M, Letzel H, et al. Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients. Klin Paediatrie 2002;214:230-5.
29. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
30. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-6.
31. Fink U, Schuhmacher C, Stein HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995;82:1248-52.
32. Langner K, Thomas M, Klinke F, et al. Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of "mediastinal downstaging". Chirurg 2003;74:42-9.
33. Thomas M, Rube C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999;17:1185.